K.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.
Cheryl Guttman Krader
Inappropriate use of a gonadotropin-releasing hormone agonist for androgen deprivation therapy of localized prostate cancer fell dramatically following implementation of reimbursement cuts mandated by the Medicare Modernization Act of 2003, but overuse remains problematic, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
Repeated injections of onabotulinumtoxinA (onabotA [Botox]), 100 U, continue to provide benefit in patients with overactive bladder syndrome and urinary incontinence and without any new safety concerns, according to results of a pre-specified interim analysis in an open-label, 3-year extension study.
Local deficiency in neutrophil gelatinase-associated lipocalin may be a contributing pathogenic factor for recurrent urinary tract infections in some children, according to research from Boston Children’s Hospital reported at the AUA annual meeting in Orlando, FL.
A study of contemporary trends in the management of upper tract calculi shows the approach to treatment is influenced by several provider-specific attributes and identifies a steady shift toward increasing use of ureteroscopy.
Continent urinary diversion and postoperative complications were found to be independent predictors of hospital readmission following radical cystectomy in an analysis from the University of Wisconsin, Madison.
Analyses of morbidity and mortality after surgery for BPH show that the current major modalities are all safe, but also identify patient attributes associated with an increased risk of complications.
Analyses of serial magnetic resonance imaging and three-dimensional renderings of those images provide proof of principle for using convective thermal heating to ablate prostate tissue, and early evidence suggests the efficacy and potential clinical advantages of using this novel technology to treat BPH, said first author Lance A. Mynderse, MD, at the European Association of Urology annual congress in Stockholm, Sweden.
Intravesical administration of a liquid liposomal formulation of onabotulinumtoxinA (“Liposomal BoNT-A,” Lipella Pharmaceuticals) shows promise as a safe and effective treatment for refractory overactive bladder (OAB), according to a pilot study presented at the European Association of Urology annual congress in Stockholm, Sweden.
Preoperative hypoalbuminemia is a risk factor for complications following radical cystectomy, say researchers from the University of North Carolina, Chapel Hill.